Cargando…

Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce

BACKGROUND: Identifying subjects at risk of imminent psoriatic arthritis (PsA) would allow these subjects to participate in therapeutic interventions to delay or prevent PsA development. METHODS: A systematic literature review (SLR) was conducted in 2021 in Medline, Embase, PubMed, Central databases...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Marco, Gabriele, Zabotti, Alen, Baraliakos, Xenofon, Iagnocco, Annamaria, Aletaha, Daniel, Gisondi, Paulo, Emmel, Jenny, Smolen, Josef S, McGonagle, Dennis G, Gossec, Laure
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Psoriatic Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314670/ https://www.ncbi.nlm.nih.gov/pubmed/37349122 http://dx.doi.org/10.1136/rmdopen-2023-003143

Ejemplares similares

Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia
por: Zabotti, Alen, et al.
Publicado: (2019)

Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis
por: Borst, Carina, et al.
Publicado: (2021)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2021)

From Psoriasis to Psoriatic Arthritis: Insights from Imaging on the Transition to Psoriatic Arthritis and Implications for Arthritis Prevention
por: Zabotti, Alen, et al.
Publicado: (2020)

MRI of psoriatic nail disease pre- and post-TNF inhibitor therapy shows persistent subclinical inflammation after 6 months despite good clinical response
por: Ash, Zoe, et al.
Publicado: (2018)

Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis
por: Dubash, Sayam, et al.
Publicado: (2022)

Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries
por: Lucasson, Florian, et al.
Publicado: (2022)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
por: Smolen, Josef S, et al.
Publicado: (2021)

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
por: Mease, Philip J, et al.
Publicado: (2020)

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
por: Gossec, Laure, et al.
Publicado: (2022)

Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study
por: Leung, Ying Ying, et al.
Publicado: (2023)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Psoriatic arthritis: an evolving matter
por: Wendling, Daniel
Publicado: (2015)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study
por: Coates, Laura C., et al.
Publicado: (2022)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Distinguishing rheumatoid arthritis from psoriatic arthritis
por: Merola, Joseph F, et al.
Publicado: (2018)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
por: Richette, Pascal, et al.
Publicado: (2023)

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis
por: Wervers, Kim, et al.
Publicado: (2018)

Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
por: Regierer, Anne Constanze, et al.
Publicado: (2023)

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
por: Ritchlin, Christopher T, et al.
Publicado: (2023)

What makes psoriatic and rheumatoid arthritis so different?
por: Veale, Douglas James, et al.
Publicado: (2015)

Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis
por: Zhang, Hanzhe, et al.
Publicado: (2021)

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
por: Mease, Philip J, et al.
Publicado: (2020)

Real-world burden of comorbidities in US patients with psoriatic arthritis
por: Shah, Kamal, et al.
Publicado: (2017)

Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis
por: Wade, Sarah M, et al.
Publicado: (2019)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2019)

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
por: Braun, Juergen, et al.
Publicado: (2023)

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
por: Smolen, Josef S, et al.
Publicado: (2020)

Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population
por: Gulati, Agnete Malm, et al.
Publicado: (2018)

Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments
por: Vandendorpe, Ann-Sophie, et al.
Publicado: (2019)

Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis
por: Michelsen, Brigitte, et al.
Publicado: (2017)

Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews
por: Ogdie, Alexis, et al.
Publicado: (2020)

Multimodal imaging of the distal interphalangeal-joint synovio-entheseal complex in psoriatic arthritis (MIDAS): a cross-sectional study on the diagnostic accuracy of different imaging modalities comparing psoriatic arthritis to psoriasis and osteoarthritis
por: Guldberg-Møller, Jørgen, et al.
Publicado: (2022)

Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study
por: Proft, Fabian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k1ilftedo4crrt2150rnj97js5